The overabundance of sugar in processed foods leads to overconsumption and unhealthy cravings, contributing to rising rates of obesity, type 2 diabetes, cardiovascular disease, and other metabolic health issues. Current approaches often focus on changing food composition or post-ingestion metabolism, rather than addressing the initial sensory experience of sweetness.

Palate Therapeutics is developing an oral oligonucleotide therapy designed to temporarily and reversibly modulate the perception of sweetness and the metabolism of sweet foods by targeting taste buds. This approach aims to promote healthier eating habits by influencing dietary choices at the point of consumption, without requiring changes to food formulations. The therapy offers a novel strategy to prevent and manage metabolic diseases by enabling individuals to re-evaluate and consciously choose healthier food options. By altering how individuals taste and perceive sweetness, Palate Therapeutics seeks to restore balanced diets and enhance overall well-being.

Oral oligonucleotide therapy targeting taste receptors

Temporary and reversible modulation of sweetness perception

Alters metabolism of sweet foods at the taste bud level

Demonstrated gene modulation lasting up to 14 days in mouse models with a single dose

Potential application as a monotherapy or in combination with GLP-1 based drugs

The primary target audience includes individuals at risk of or suffering from metabolic diseases such as obesity and type 2 diabetes, as well as those seeking to adopt healthier eating habits.